Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Wave Life Sciences hits tumultuous waters as ax comes crashing down on staffers
Fierce Biotech
Mon, 02/10/20 - 10:31 am
Wave Life Sciences
layoffs
Duchenne Muscular Dystrophy
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs
Xconomy
Wed, 01/22/20 - 06:41 pm
Sarepta Therapeutics
Vyondys 53
Duchenne Muscular Dystrophy
FDA
Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track
Xconomy
Thu, 01/9/20 - 10:35 am
Solid Biosciences
gene therapy
reorganization
Duchenne Muscular Dystrophy
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Tue, 12/24/19 - 12:00 am
Roche
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
SRP-9001
Wave Stock Crashes After Decision to Halt Duchenne Drug Studies
Xconomy
Mon, 12/16/19 - 10:35 pm
Wave Life Sciences
Duchenne Muscular Dystrophy
suvodirsen
clinical trials
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Mon, 12/16/19 - 10:52 am
Axsome Therapeutics
AXS-05
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
major depressive disorder
Intra-Cellular Therapies
lumateperone
schizophrenia
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Biopharma Dive
Fri, 12/13/19 - 12:28 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Vyondys 53
Wave faces key test in bid to challenge Sarepta in DMD
Biopharma Dive
Sat, 11/30/19 - 11:18 pm
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity
Stat
Tue, 11/12/19 - 09:52 am
Solid Biosciences
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
SGT-001
Roche joins others in dropping myostatin inhibitor for DMD
Pharmaforum
Fri, 11/8/19 - 10:50 am
Roche
Duchenne Muscular Dystrophy
RG6206
myostatin inhibitors
Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug
Stat
Thu, 11/7/19 - 10:58 pm
Sarepta Therapeutics
Doug Ingram
FDA
Vyondys 53
Duchenne Muscular Dystrophy
Sarepta competitor files with FDA for Duchenne drug
Seeking Alpha
Wed, 10/2/19 - 12:12 pm
Sarepta Therapeutics
NS Pharma
golodirsen
FDA
Duchenne Muscular Dystrophy
Wave takes a different tack from Sarepta in Duchenne
EP Vantage
Thu, 09/12/19 - 10:33 am
Wave Life Sciences
Duchenne Muscular Dystrophy
suvodirsen
Sarepta Therapeutics
The FDA and Sarepta: a window into the real world of drug regulation
Stat
Tue, 09/3/19 - 04:42 pm
FDA
regulatory
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Vyondys 53
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Endpoints
Tue, 08/27/19 - 11:01 pm
Santhera
Duchenne Muscular Dystrophy
clinical trials
vamorolone
RaveraGen
Sarepta now needs flawless progress for gene therapy
Biopharma Dive
Tue, 08/20/19 - 10:58 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
Vyondys 53
gene therapy
SRP-9001
Sarepta Duchenne drug rejected by FDA in surprise decision
Biopharma Dive
Mon, 08/19/19 - 11:48 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
complete response letter
Vyondys 53
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
Yahoo/Zacks.com
Mon, 08/19/19 - 10:54 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Bloomberg
Mon, 08/19/19 - 10:28 am
Sarepta Therapeutics
analysts
Duchenne Muscular Dystrophy
Vyondys 53
Exondys 51
Patient in Sarepta gene therapy trial develops serious illness; shares plunge
Yahoo/Reuters
Thu, 08/8/19 - 11:34 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
rhabdomyolysis
gene therapy
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »